ANI Pharmaceuticals 향후 성장

Future 기준 점검 4/6

ANI Pharmaceuticals (는) 각각 연간 26.9% 및 8.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 19.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 23.5% 로 예상됩니다.

핵심 정보

26.9%

이익 성장률

19.83%

EPS 성장률

Pharmaceuticals 이익 성장	14.4%
매출 성장률	8.2%
향후 자기자본이익률	23.48%
애널리스트 커버리지	Good
마지막 업데이트	23 Dec 2025

최근 향후 성장 업데이트

Recent updates

ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates

Oct 28

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Aug 10

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

Jun 21

We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation

May 16

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth

Mar 28

Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector

Sep 15 Accelerating demand for their lead Rare Disease asset and growth in generics, along with expanding sales efforts, are expected to significantly boost revenues.

There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

Sep 10

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Aug 14

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

Aug 08

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Sep 22

이익 및 매출 성장 예측

NasdaqGM:ANIP - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	1,052	N/A	218	220	5
12/31/2026	955	60	161	196	7
12/31/2025	870	63	154	170	7
9/30/2025	827	34	135	171	N/A
6/30/2025	747	-13	104	139	N/A
3/31/2025	674	-22	49	81	N/A
12/31/2024	614	-20	47	64	N/A
9/30/2024	555	-9	74	93	N/A
6/30/2024	539	24	94	113	N/A
3/31/2024	517	31	95	116	N/A
12/31/2023	487	15	100	119	N/A
9/30/2023	449	10	53	70	N/A
6/30/2023	401	-8	19	41	N/A
3/31/2023	359	-28	-7	9	N/A
12/31/2022	316	-50	-48	-31	N/A
9/30/2022	283	-69	-53	-39	N/A
6/30/2022	251	-65	-52	-48	N/A
3/31/2022	226	-63	-61	-36	N/A
12/31/2021	216	-43	-20	3	N/A
9/30/2021	212	-22	-16	10	N/A
6/30/2021	213	-17	-17	14	N/A
3/31/2021	213	-15	23	34	N/A
12/31/2020	208	-23	-53	15	N/A
9/30/2020	199	-24	-42	26	N/A
6/30/2020	198	-20	-15	49	N/A
3/31/2020	203	-1	-32	33	N/A
12/31/2019	207	6	18	46	N/A
9/30/2019	216	16	41	68	N/A
6/30/2019	215	17	N/A	55	N/A
3/31/2019	208	14	N/A	58	N/A
12/31/2018	202	15	N/A	67	N/A
9/30/2018	192	0	N/A	56	N/A
6/30/2018	189	0	N/A	64	N/A
3/31/2018	187	0	N/A	56	N/A
12/31/2017	177	-1	N/A	39	N/A
9/30/2017	168	7	N/A	36	N/A
6/30/2017	158	5	N/A	20	N/A
3/31/2017	145	4	N/A	23	N/A
12/31/2016	129	4	N/A	27	N/A
9/30/2016	108	8	N/A	20	N/A
6/30/2016	90	10	N/A	29	N/A
3/31/2016	78	12	N/A	27	N/A
12/31/2015	76	15	N/A	17	N/A
9/30/2015	79	33	N/A	23	N/A
6/30/2015	77	35	N/A	17	N/A
3/31/2015	64	30	N/A	18	N/A
12/31/2014	56	29	N/A	22	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ANIP 의 연간 예상 수익 증가율(26.9%)이 saving rate(3.3%)보다 높습니다.

수익 vs 시장: ANIP 의 연간 수익(26.9%)이 US 시장(16.2%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: ANIP 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: ANIP 의 수익(연간 8.2%)이 US 시장(연간 10.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: ANIP 의 수익(연간 8.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ANIP의 자본 수익률은 3년 후 23.5%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/29 16:14
종가	2025/12/26 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

ANI Pharmaceuticals, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Glen Santangelo	Barclays
Dewey Steadman	Canaccord Genuity
Timothy Chiang	Capital One Securities, Inc.

ANI Pharmaceuticals 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

ANI Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2025

Ani Pharmaceuticals, Inc. Raises Earnings Guidance for the Year 2025

ANI Pharmaceuticals, Inc. Raises Earnings Guidance for the Year 2025

ANI Pharmaceuticals, Inc. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Full Year 2025

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

Recent updates

Ani Pharmaceuticals, Inc. Announces Board Changes

ANI Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2025

ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates

ANI Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 07, 2025

ANI Pharmaceuticals, Inc. Announces New Day Clinical Trial Results to Be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Ani Pharmaceuticals, Inc. Raises Earnings Guidance for the Year 2025

ANI Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 08, 2025

ANI Pharmaceuticals, Inc. Announces Results from New Day Clinical Trial of ILUVIEN®? for Use in Patients with Diabetic Macular Edema (DME)

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 2500 Value Index

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals, Inc. Announces Presentation of New Preclinical Data

Ani Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin Gel for the Treatment of Acute Gout Flares

We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation

ANI Pharmaceuticals, Inc. Raises Earnings Guidance for the Year 2025

ANI Pharmaceuticals, Inc. Announces Presentation of Preclinical Data on the Use of Purified Cortrophin®? Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

ANI Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 09, 2025

ANI Pharmaceuticals, Inc., Annual General Meeting, May 22, 2025

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth

Ani Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

ANI Pharmaceuticals, Inc. Announces FDA Approval for Expansion of ILUVIEN®? Label

ANI Pharmaceuticals, Inc. Announces FDA Approval of New Purified Cortrophin Gel®? Prefilled Syringe

ANI Pharmaceuticals, Inc. Reports Intangible Asset Impairment Charge for the Fourth Quarter Ended December 31, 2024

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 28, 2025

ANI Pharmaceuticals: More Than Just A Generics Company

ANI Pharmaceuticals, Inc. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Full Year 2025

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day Cgt Exclusivity

ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares

Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock